Related references
Note: Only part of the references are listed.The master switch: The role of mast cells in autoimmunity and tolerance
Blayne A. Sayed et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Development and dynamics of robust T-cell responses to CML under imatinib treatment patients
Christiane I-U. Chen et al.
BLOOD (2008)
An evaluation of the cardiotoxicity of imatinib mesylate
Antonio Luiz Ribeiro et al.
LEUKEMIA RESEARCH (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Immunomodulatory mast cells: negative, as well as positive, regulators of immunity
Stephen J. Galli et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Defective T cell development and function in the absence of Abelson kinases
Jing Jin Gu et al.
JOURNAL OF IMMUNOLOGY (2007)
Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches
Agnieszka Czechowicz et al.
SCIENCE (2007)
Modulation of T-effector function by imatinib at the level of cytokine secretion
Christoph Leder et al.
EXPERIMENTAL HEMATOLOGY (2007)
Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse
Helene Bour-Jordan et al.
JOURNAL OF IMMUNOLOGY (2007)
Amelioration of diabetes by imatinib mesylate (Gleevec®):: role of β-cell NF-κB activation and anti-apoptotic preconditioning
Robert Hagerkvist et al.
FASEB JOURNAL (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro
Robert Hagerkvist et al.
CELL BIOLOGY INTERNATIONAL (2006)
Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections
Sabine Mumprecht et al.
BLOOD (2006)
Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat
Rhonda Geoffrey et al.
JOURNAL OF IMMUNOLOGY (2006)
Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease
F. Magro et al.
INFLAMMATORY BOWEL DISEASES (2006)
Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation
R. Lee Reinhardt et al.
JOURNAL OF IMMUNOLOGY (2006)
α1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice
Yuanqing Lu et al.
HUMAN GENE THERAPY (2006)
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors
J Guo et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
QZ Tang et al.
NATURE IMMUNOLOGY (2006)
Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice
A Sadanaga et al.
ARTHRITIS AND RHEUMATISM (2005)
The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation
AM Wolf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
α1-antitrypsin monotherapy prolongs islet allograft survival in mice
EC Lewis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A comprehensive review of interventions in the NOD mouse and implications for translation
LKM Shoda et al.
IMMUNITY (2005)
A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
KC Herold et al.
DIABETES (2005)
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
AL Dewar et al.
BLOOD (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways
S Appel et al.
CLINICAL CANCER RESEARCH (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: Therapeutic efficacy and mechanism of protection against type 1 diabetes
W Chen et al.
ENDOCRINOLOGY (2004)
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
AB Dietz et al.
BLOOD (2004)
Insight into the physiological functions of PDGF through genetic studies in mice
C Betsholtz
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate
N Boissel et al.
LEUKEMIA (2004)
Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
K Miyachi et al.
CLINICAL RHEUMATOLOGY (2003)
Imatinib for systemic mast-cell disease
A Pardanani et al.
LANCET (2003)
Identification of the β cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes
SM Lieberman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
A Pardanani et al.
BLOOD (2003)
Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases
KK Eklund et al.
ANNALS OF MEDICINE (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour
S Miyagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice
V Judkowski et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
